drugset / Trial / NCT04466826

Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients

NCT04466826 ↗

NaSequentialOpen-labelTreatment

Summary

Single-center, open-label, pre-post treatment pilot study to evaluate the safety and effectiveness of sphenopalatine ganglia blocks for the treatment of chronic migraine in the pediatric population. 50 children with a diagnosis of chronic migraines will undergo a series of three transnasal sphenopalatine ganglia blocks to measure their effect on headache frequency, headache intensity, headache duration, and use of headache medication.

Timeline

Start
2021-01-02
Primary completion
2021-02-05
Completion
2021-02-05

Outcome

Outcome not reported

Stopped (Enrollment): “Low enrollment”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Bupivacaine Other / unclassified 0.3 ml Intranasal
Background Bupivacaine Other / unclassified 0.5 % Intranasal